News Search Results
Dec 17, 2025, 09:45 ET Insightec Announces Spin-Out of Lotus Neuro to Advance Focused Ultrasound Brain Therapies
pioneering the use of focused ultrasound to transform patient care, today announced the spin-out and launch of Lotus Neuro, a new clinical stage biotechnology company advancing the next generation of brain‑targeted therapeutics through precision, low frequency focused ultrasound. This launch marks a pivotal
More news about: INSIGHTEC
Dec 17, 2025, 09:45 ET Insightec Announces Spin-Out of Lotus Neuro to Advance Focused Ultrasound Brain Therapies
pioneering the use of focused ultrasound to transform patient care, today announced the spin-out and launch of Lotus Neuro, a new clinical stage biotechnology company advancing the next generation of brain‑targeted therapeutics through precision, low frequency focused ultrasound. This launch marks a pivotal
More news about: INSIGHTEC
Dec 17, 2025, 09:04 ET HED Accelerates Innovation and Impact: Celebrating 2025 Achievements, Shaping the Future of Integrated Design
California Project Achievement Award for Saddleback College Gateway Building.AIA San Diego Merit Award for MiraCosta College Chemistry and Biotechnology Building.Phius Passive Projects Design Competition Honorable Mention for Conservatory Apartments.SCANPH "Homes Within Reach" Award
More news about: HED
Dec 17, 2025, 09:00 ET Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants
MONTREAL, Dec. 17, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias and cardiometabolic diseases,
More news about: Thryv Therapeutics Inc.
Dec 17, 2025, 08:47 ET NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio
into a multiproduct clinical stage oncology company and successfully took the company public with a listing on the NASDAQ exchange. Prior to his biotechnology CEO roles, David spent over 20 years in a variety of executive roles with Eli Lilly and Boehringer Ingelheim."We believe David is a great
More news about: NanOlogy, LLC
Dec 17, 2025, 08:30 ET Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Dec 17, 2025, 08:01 ET Nona Biosciences and Valink Therapeutics Form Strategic Alliance to Accelerate Novel Biologics Discovery
/PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company providing integrated solutions for biological drug discovery and development from "Idea to IND" (I to I®), and Valink Therapeutics ("Valink"), a private biotechnology company developing next-generation therapeutics with
More news about: Nona Biosciences
Dec 17, 2025, 08:00 ET The Colossal Foundation Doubles Funding to $100 Million to Prevent Mass Extinctions
Foundation's new $50M in funding will help bridge this chasm by enabling smarter, faster, and more scalable conservation efforts powered by breakthrough biotechnology."Traditional conservation remains essential but is no longer sufficient on its own. With wildlife populations plummeting and ecosystems unraveling,
More news about: The Colossal Foundation
Dec 17, 2025, 07:52 ET Norgine mejora su cartera de productos de hepatología y especialidades
exclusivo con Vir BiotechnologyEl acuerdo subraya la misión de Norgine de ofrecer terapias innovadoras a los pacientes y consolida nuestra trayectoria en hepatología y productos farmacéuticos especializados.El candidato de Vir Biotechnology para el tratamiento
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 07:30 ET Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Dec 17, 2025, 05:30 ET Norgine potenzia il portafoglio di prodotti epatologici e speciali attraverso un accordo di licenza esclusivo concluso con Vir Biotechnology
In base ai termini dell'accordo di licenza, Vir Biotechnology riceverà un rimborso iniziale di 55 milioni di euro e fino a 495 milioni di euro in potenziali pagamenti per traguardi normativi e commerciali. Inoltre Vir Biotechnology riceverà royalty scaglionate, da metà ad alta percentuale del
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 05:23 ET Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology
Im Rahmen der Lizenzvereinbarung erhält Vir Biotechnology eine erste Erstattungszahlung in Höhe von 55 Mio. Euro und bis zu 495 Mio. Euro in Form von potenziellen regulatorischen und kommerziellen Meilensteinzahlungen. Darüber hinaus erhält Vir Biotechnology gestaffelte Lizenzgebühren in Höhe von mittleren
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 04:00 ET Slone Partners Places Jeffrey Kasten as Chief Business Officer at Vertero Therapeutics
Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment.
More news about: Slone Partners
Dec 17, 2025, 03:01 ET Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
Under the terms of the licensing agreement, Vir Biotechnology will receive a EUR 55 million initial reimbursement payment and up to EUR 495 million in potential regulatory and commercial milestone payments. Additionally, Vir Biotechnology will receive tiered, mid-teen to high-twenties percent royalties
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 03:01 ET Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
Under the terms of the licensing agreement, Vir Biotechnology will receive a EUR 55 million initial reimbursement payment and up to EUR 495 million in potential regulatory and commercial milestone payments. Additionally, Vir Biotechnology will receive tiered, mid-teen to high-twenties percent royalties
More news about: Norgine Pharmaceuticals Limited
Dec 16, 2025, 22:55 ET Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten
More news about: Kodiak Sciences Inc.
Dec 16, 2025, 15:40 ET Improve Effectiveness of Cardiac Assessments in Early Phase Trials with Early Precision QT and AI-powered Data Quality Checks, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Dec 16, 2025, 15:39 ET Bioassay Method Transfer Strategies to Reduce Variability, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Dec 16, 2025, 15:35 ET Medical Device Validation Solutions for Evolving Industry Needs, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Dec 16, 2025, 10:50 ET Pharmaceutical Filtration Market is expected to generate a revenue of USD 55.21 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®
Global Bioprocess Technology Market Size By Product (Bioprocess Instruments, Bioprocess Services), By Application (Pharmaceuticals, Biotechnology, Food and Beverage, Environmental Management), By End User (Biopharmaceutical Companies, Academic and Research Institutes, Contract Manufacturing
More news about: Verified Market Research
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
numerous public and private biotechnology companies, including leadership roles as Chair of Aurinia Pharmaceuticals, ESSA Pharma, enGene, and has held board positions at Eupraxia Pharmaceuticals and Cardiome / Correvio Pharma, amongst others, where he helped scale emerging biotechnology companies into globally
More news about: Specific Biologics Inc.
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
numerous public and private biotechnology companies, including leadership roles as Chair of Aurinia Pharmaceuticals, ESSA Pharma, enGene, and has held board positions at Eupraxia Pharmaceuticals and Cardiome / Correvio Pharma, amongst others, where he helped scale emerging biotechnology companies into globally
More news about: Specific Biologics Inc.
Dec 16, 2025, 10:00 ET Lilly to participate in J.P. Morgan Healthcare Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 16, 2025, 08:46 ET Aces Diagnostics Announces Key Development Partnerships for Novel LymeSeek™ Test
PHOENIX, Dec. 16, 2025 /PRNewswire/ -- Aces Diagnostics Inc., a biotechnology company dedicated to delivering accurate and accessible diagnostics for Lyme disease, announced significant progress toward commercialization of
More news about: Aces Diagnostics
Dec 16, 2025, 08:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
SHANGHAI, Dec. 16, 2025 /PRNewswire/ -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developing advanced antibody-drug conjugates (ADCs) and multi-specific antibody therapeutics for oncology and immunology, today
More news about: Allink Biotherapeutics